SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant ...

Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the ...

The Utah-based pharmaceutical company has trained a large language model to enable scientists to tap into dozens of machine learning models at once, saving them time during drug development.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence.